AB Science SA
PAR:AB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
AB Science SA
Total Current Liabilities
AB Science SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AB Science SA
PAR:AB
|
Total Current Liabilities
€18.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
1%
|
|
|
Sanofi SA
PAR:SAN
|
Total Current Liabilities
€28.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Ipsen SA
PAR:IPN
|
Total Current Liabilities
€1.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
12%
|
|
|
Vetoquinol SA
PAR:VETO
|
Total Current Liabilities
€133.9m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Virbac SA
PAR:VIRP
|
Total Current Liabilities
€516.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
4%
|
|
|
Medincell SA
PAR:MEDCL
|
Total Current Liabilities
€21.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
AB Science SA
Glance View
AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. The company is headquartered in Paris, Ile-De-France and currently employs 96 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.
See Also
What is AB Science SA's Total Current Liabilities?
Total Current Liabilities
18.4m
EUR
Based on the financial report for Jun 30, 2025, AB Science SA's Total Current Liabilities amounts to 18.4m EUR.
What is AB Science SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
1%
Over the last year, the Total Current Liabilities growth was 5%. The average annual Total Current Liabilities growth rates for AB Science SA have been -1% over the past three years , -5% over the past five years , and 1% over the past ten years .
